Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Sep 06
Have your own idea? Try our Stock Screener
Markets has moved to Discover
You can now access Markets by navigating to Discover and selecting Markets.
Indian (NIFTY) Clinical Research and Equipment Industry Analysis
UpdatedSep 20, 2024
DataAggregated Company Financials
Companies17
- 7D-2.2%
- 3M20.9%
- 1Y37.3%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.2%, driven by declines in Indegene and Divi's Laboratories of 9.0% and 1.0%, respectively. Meanwhile, Tarsons Products actually outperformed within the industry, gaining 5.4% in the last week. This takes the industry's 12 month performance to a gain of 37%. Earnings are forecast to grow by 21% annually.
Industry Valuation and Performance
Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 20 Sep 2024 | ₹2.3t | ₹247.6b | ₹26.3b | 48.7x | 86.5x | 9.2x |
| Sun, 18 Aug 2024 | ₹1.9t | ₹205.3b | ₹23.8b | 37.1x | 78.3x | 9.1x |
| Tue, 16 Jul 2024 | ₹1.8t | ₹202.0b | ₹23.9b | 38.1x | 75x | 8.9x |
| Thu, 13 Jun 2024 | ₹1.7t | ₹194.5b | ₹21.5b | 34.2x | 80x | 8.9x |
| Sat, 11 May 2024 | ₹1.4t | ₹168.0b | ₹18.7b | 29x | 74.9x | 8.3x |
| Mon, 08 Apr 2024 | ₹1.4t | ₹168.5b | ₹18.6b | 28.6x | 76.7x | 8.5x |
| Wed, 06 Mar 2024 | ₹1.3t | ₹168.5b | ₹18.6b | 32.2x | 72.5x | 8x |
| Fri, 02 Feb 2024 | ₹1.4t | ₹166.7b | ₹19.0b | 31.6x | 74.1x | 8.4x |
| Sun, 31 Dec 2023 | ₹1.4t | ₹155.9b | ₹18.1b | 21.6x | 78.2x | 9.1x |
| Tue, 28 Nov 2023 | ₹1.4t | ₹155.9b | ₹18.1b | 22.6x | 77x | 8.9x |
| Thu, 26 Oct 2023 | ₹1.3t | ₹156.1b | ₹19.8b | 23.1x | 64.3x | 8.2x |
| Sat, 23 Sep 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 24.6x | 70.4x | 9x |
| Mon, 21 Aug 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 26.6x | 70.2x | 8.9x |
| Wed, 19 Jul 2023 | ₹1.4t | ₹156.5b | ₹23.0b | 30.7x | 59.1x | 8.7x |
| Fri, 16 Jun 2023 | ₹1.3t | ₹157.2b | ₹23.0b | 28.2x | 57.8x | 8.5x |
| Sun, 14 May 2023 | ₹1.2t | ₹163.0b | ₹28.6b | 33.7x | 43.3x | 7.6x |
| Tue, 11 Apr 2023 | ₹1.1t | ₹159.5b | ₹28.4b | 32.2x | 38.6x | 6.9x |
| Thu, 09 Mar 2023 | ₹1.1t | ₹159.5b | ₹28.4b | 31.4x | 37.4x | 6.7x |
| Sat, 04 Feb 2023 | ₹1.1t | ₹166.4b | ₹34.5b | 26.9x | 31x | 6.4x |
| Mon, 02 Jan 2023 | ₹1.2t | ₹164.9b | ₹34.5b | 30.9x | 35.5x | 7.4x |
| Wed, 30 Nov 2022 | ₹1.2t | ₹164.9b | ₹34.5b | 29.9x | 35.4x | 7.4x |
| Fri, 28 Oct 2022 | ₹1.3t | ₹164.1b | ₹36.1b | 34.8x | 35.6x | 7.8x |
| Sun, 25 Sep 2022 | ₹1.3t | ₹162.5b | ₹35.7b | 37.3x | 35.7x | 7.9x |
| Tue, 23 Aug 2022 | ₹1.3t | ₹162.6b | ₹35.8b | 36.7x | 35.5x | 7.8x |
| Thu, 21 Jul 2022 | ₹1.3t | ₹158.3b | ₹34.2b | 33.6x | 38.8x | 8.4x |
| Sat, 18 Jun 2022 | ₹1.2t | ₹158.3b | ₹34.2b | 31.2x | 35.6x | 7.7x |
| Mon, 16 May 2022 | ₹1.4t | ₹149.7b | ₹30.1b | 32.9x | 47.4x | 9.5x |
| Wed, 13 Apr 2022 | ₹1.5t | ₹148.3b | ₹29.4b | 38.6x | 52.7x | 10.4x |
| Fri, 11 Mar 2022 | ₹1.5t | ₹148.3b | ₹29.4b | 35.3x | 50x | 9.9x |
| Sun, 06 Feb 2022 | ₹1.5t | ₹138.5b | ₹24.5b | 38.6x | 60.5x | 10.7x |
| Tue, 04 Jan 2022 | ₹1.6t | ₹137.8b | ₹24.6b | 33.3x | 64.7x | 11.5x |
| Thu, 02 Dec 2021 | ₹1.6t | ₹137.6b | ₹24.4b | 30x | 66x | 11.7x |
| Sat, 30 Oct 2021 | ₹1.7t | ₹132.2b | ₹22.7b | 23x | 73.1x | 12.6x |
| Mon, 27 Sep 2021 | ₹1.7t | ₹131.1b | ₹22.9b | 23.8x | 73.7x | 12.9x |
Price to Earnings Ratio
73.7x
Current Industry PE
- Investors are optimistic on the Indian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 86.5x which is higher than its 3-year average PE of 57.9x.
- The industry is trading close to its 3-year average PS ratio of 8.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 4.6% per year over the last three years.
- Revenues for these companies have grown 24% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Indian Clinical Research and Equipment compare with similar industries?
| IN Market | -0.71% | |
| Healthcare | -2.02% | |
| Life Sciences | -2.18% | |
| Clinical Research and Equipment | -2.18% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TARSONS Tarsons Products | ₹468.35 | 5.4% +₹1.3b | -13.2% | PE67.2x | |
| INNOVACAP Innova Captab | ₹773.80 | 1.9% +₹838.3m | n/a | PE41.7x | |
| 539267 Samsrita Labs | ₹30.03 | 66.8% +₹178.1m | 76.8% | PB3.6x | |
| 540729 Vanta Bioscience | ₹46.06 | 9.3% +₹24.6m | 10.3% | PS3x |
